This represents a 44% increase between 1990 and 2010. A recent estimate suggests that HCV attributable to injecting drug use added around half a million DALYs to the global burden of disease in 2010. 6 Very few PWID currently seek HCV treatment, but dramatic improvements in treatment efficacy and reduced treatment length, complexity and toxicity are likely to increase treatment uptake among PWID in the future. 7, 8 Australia has a well-established opioid substitution treatment (OST) program and many clinics offer blood-borne virus testing, but this is not necessarily delivered on-site, 9 limiting access for clients. OST clinics, however, provide a potential access point for HCV testing, management and treatment 10 and may play an important role in the roll-out of the new treatments in the future. 7 The prevalence and incidence of HCV among PWID in Australia is well-established and decreasing. 11, 12 However, there have been few recent prevalence studies of OST clients exclusively, who -given their longer injecting careers -are likely to have a higher prevalence than other drug injectors and consequently be in more immediate need of HCV management. It is important to determine both the prevalence of HCV among OST clients and their knowledge of their HCV status to ensure appropriate targeting and planning of future HCV screening and treatment activities. The current study uses a large sample of opioid dependent people recruited in New South Wales, Australia. The study aims are to:
1. Determine the prevalence of HCV infection (antibody and RNA status) among private and public OST clients in NSW. Respondents were eligible if they were aged 18 years or over; had an adequate understanding of English; and had participated in opioid pharmacotherapy maintenance treatment for opioid dependence. Participants reporting recent suicidal intent or who were found to be currently experiencing psychosis were excluded from the study. HCV results and interview data were obtained for 1,484 of the 1,511 participants (both results were required to be included in the current analysis).
Hepatitis

Structured interview
Detailed information regarding the structured interview has been published previously. 
Blood sample
Providing a viable blood sample was necessary for participation. A venepuncturist took one to five 10 mL tubes of blood from each participant, depending on vein health. These samples were transferred on the day of collection to the Virology Laboratory at the Prince of Wales Hospital for processing. Plasma was tested for HCV IgG antibodies using the ADVIA Centaur HCV enzyme immunoassay (Siemens), according to manufacturer's instructions.
HCV antibody negative (anti-HCV-) samples were tested using a validated method in pools of five for HCV RNA using transposon mediated amplification (TMA, Versant Siemens). HCV antibody positive (anti-HCV+) samples were tested for HCV viral load using a quantitative real-time reverse-transcriptase polymerase chain reaction as described .
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Statistical analysis
Bivariate analyses were conducted using cross tabulations for dichotomous variables, and t-tests for continuous variables. Logistic regression models were run to compare those who correctly reported their HCV status to those who incorrectly reported it. Separate models were run for two groups of participants: (1) those who were anti-HCV-; and (2) those were anti-HCV+.
Variables were included in logistic regression models if p<0.05 in the bivariate comparisons. Age and sex were included to control for potential demographic differences. Nonsignificant variables were dropped from the final models. Alpha level was set at p<0.05.
Results are reported in terms of odds ratios (OR) and 95% confidence intervals (95%CI) for categorical outcomes, and t-tests for continuous outcomes. All analyses were conducted in SPSS Statistics (v20).
Results
Prevalence of HCV
Eighty-four per cent of participants (n=1,242) were anti-HCV+ and, of these, 808 (65%) were RNA+. Nine anti-HCV-participants were RNA+, indicating recent infection ( Figure 1 ). Of those who had been injecting for ≤1 year (n=44), 59% were anti-HCV+ compared with 87% of participants who had been injecting for >1 year (OR 3.16, 95%CI 2.16-4.62). 
Opioid Use HCV testing and status among OST clients
Sample characteristics: demographics, substance use and injection behaviours
Participants were typically in their mid to late 30s, had commenced opioid use prior to the age of 20 and first injected shortly after age 20 (Table 1) . Ninety-nine per cent had ever injected drugs; 93% had injected drugs daily and reported an average of 15 years of injecting. The majority of participants were male, currently unemployed and had a prison history (Table 1) . More than one-quarter had ever been paid for sex, almost half had ever injected in prison.
There were substantial demographic and drug use differences between anti-HCV positive and negative participants, with anti-HCV+ participants likely to be older, unemployed, to meet criteria for a range of substance use disorders, to have injected in prison, engaged in paid sex work, and have a more extensive opioid injecting career (Table  1) . Those who were anti-HCV+ were also more likely to have spent time in prison, injected in prison or in illegal 'shooting galleries' , be alcohol dependent, have experienced multiple overdoses and have engaged in paid sex work.
Awareness of HCV status
Of those who were anti-HCV+, almost a quarter (23%) either did not know their HCV status or thought they were anti-HCV-. Of those who were anti-HCV-, 15% thought they were anti-HCV+ or did not know their HCV status. Where participants were both anti-HCV+ and RNA+, 82% correctly reported their HCV status as positive.
Predictors of incorrect reporting of anti-HCV status
In bivariate comparisons among anti-HCV+ participants, incorrect reporting was associated with being RNA-, being unmarried, no lifetime diagnosis of sedative dependence, and ever having injected drugs in prison. Among anti-HCV-participants, incorrect reporting was associated with being male, RNA-, and no lifetime diagnosis of stimulant dependence ( In the multivariate analysis for participants who were anti-HCV+, incorrect reporting was associated with being unmarried, RNAand injecting drugs in prison, and weakly associated with a shorter injecting career. Among those who were anti-HCV-, males and those who were RNA-were more likely to incorrectly report their HCV status (Table 3) .
Discussion
This study examined OST clients' HCV prevalence and their knowledge of their HCV status. The prevalence of anti-HCV among participants in this sample (84%), although higher than that found in other Australian (range 41% to 68%) and international studies of PWID (midpoint estimate of global prevalence 67%), is consistent with earlier Australian samples of OST clients. 19 This is the first large OST-specific assessment of HCV prevalence among OST clients since the reported overall decline of HCV incidence in Australia. 20 The high prevalence found in this sample compared with studies of PWID indicates that more needs to be done to prevent HCV 
Limitations
This was a cross-sectional, retrospective study, limiting the extent to which we can make causal inferences. Participants were not asked how much time had elapsed since their last HCV test or how many times they had been tested. This variable might have explained some of the variation in knowledge of HCV status, since more recent testing is likely to provide a more accurate assessment of current HCV status.
Implications
The prevalence of HCV among OST clients in NSW (84%) is much higher than PWID (cf 50% NSP clients). 11 Australia has well-established treatment services for opioid dependence, which means this population should have good access to HCV testing and referral services. There is a need to understand why a significant number of these individuals reported their HCV status incorrectly. Improved access to BBV screening, ideally on-site, with appropriately targeted pre-and post-test counselling may improve HCV status knowledge among this group and provide important opportunities for management, prevention and treatment.
Conclusions
Anti-HCV among OST clients is much higher than that reported for PWID in New South Wales. Moreover, more than one-fifth of this large sample of OST clients did not know their HCV status, highlighting the need for better HCV testing and management of OST clients in NSW. Incorrect knowledge among both anti-HCV+ and anti-HCV-participants is likely to increase risky injecting behaviours.
